Literature DB >> 7692372

PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas.

M S Trimble1, J H Xin, C T Guy, W J Muller, J A Hassell.   

Abstract

Transgenic mice bearing the rat neu proto-oncogene under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter develop focal mammary adenocarcinomas after long latency that are metastatic to the lung in a high percentage of the tumor-bearing animals. Because expression of the neu gene in the mammary epithelium precedes the occurrence of tumors, it appears that another genetic event in addition to neu transgene expression is required for tumorigenesis. We have investigated the expression of PEA3, a new member of the ets oncogene family of transcriptional regulatory factors, in neu-induced mammary tumors to learn whether PEA3 plays a role in tumor progression in this organ. We observed high levels of PEA3 RNA in neu-induced tumors, but little, if any, PEA3 RNA in the surrounding mammary epithelium. Moreover, mammary tumors that had metastasized to the lung also overexpressed the PEA3 gene, whereas normal lung tissue did not. Similar results were obtained after analyses of other transgenic mouse lines bearing metastatic mammary tumors induced by polyomavirus middle T antigen. These findings suggest that enhanced expression of PEA3 may be required to facilitate mammary tumor progression and metastasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692372

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Male sexual dysfunction in mice bearing targeted mutant alleles of the PEA3 ets gene.

Authors:  M A Laing; S Coonrod; B T Hinton; J W Downie; R Tozer; M A Rudnicki; J A Hassell
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 2.  Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis.

Authors:  Natasza A Kurpios; Nancy A Sabolic; Trevor G Shepherd; Gina M Fidalgo; John A Hassell
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

Review 3.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

4.  The ets-related mouse Pea3 gene maps to distal chromosome 11.

Authors:  K Noben-Trauth; J K Naggert; P M Nishina
Journal:  Mamm Genome       Date:  1996-07       Impact factor: 2.957

5.  The ETS family member ERM contains an alpha-helical acidic activation domain that contacts TAFII60.

Authors:  P A Defossez; J L Baert; M Monnot; Y de Launoit
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

Review 6.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

Review 7.  Notch inhibitors for cancer treatment.

Authors:  Ingrid Espinoza; Lucio Miele
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

8.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1.

Authors:  Nikhil Tyagi; Sachin K Deshmukh; Sanjeev K Srivastava; Shafquat Azim; Aamir Ahmad; Ahmed Al-Ghadhban; Ajay P Singh; James E Carter; Bin Wang; Seema Singh
Journal:  Mol Cancer Res       Date:  2017-11-08       Impact factor: 5.852

10.  Pea3 transcription factors and wnt1-induced mouse mammary neoplasia.

Authors:  Rebecca Baker; Claire V Kent; Rachel A Silbermann; John A Hassell; Lawrence J T Young; Louise R Howe
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.